Milrinon Tillomed (Milrinone)

Milrinone, the active ingredient in Milrinon Tillomed, is a phosphodiesterase‑3 inhibitor presented as a sterile intravenous solution for infusion use. It is employed to improve cardiac contractility and reduce vascular resistance in patients with acute decompensated heart failure or cardiogenic shock.

GNH USA supplies Milrinon Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Milrinone acts as a phosphodiesterase‑3 inhibitor to support cardiac function in critical heart conditions.

Acute decompensated heart failure: enhances myocardial contractility and lowers pulmonary congestion. Cardiogenic shock: provides inotropic and vasodilatory support to maintain systemic perfusion. Low cardiac output syndrome after cardiac surgery: improves cardiac output when conventional therapy is insufficient.

Milrinone may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Hypotension: drop in blood pressure after infusion. - Headache: mild to moderate intensity. - Arrhythmias: premature ventricular contractions or tachycardia. - Nausea: occasional gastrointestinal upset. - Flushing: transient warmth and redness of skin. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: profound blood pressure fall requiring intervention. - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: reduced blood flow to heart muscle. - Thrombocytopenia: low platelet count. - Anaphylactic reactions: rare allergic responses. - Cardiac arrest: sudden loss of heart function.

Milrinone requires careful monitoring and specific safety measures before and during therapy.

Cardiac monitoring: continuous ECG and hemodynamic assessment are recommended. Electrolyte balance: correct potassium and magnesium levels to reduce arrhythmia risk. Renal impairment: adjust dosing in patients with reduced kidney function. Concomitant vasodilators: use cautiously to avoid excessive hypotension. Pregnancy and lactation: safety not established; weigh benefits against potential risks. Store at ambient temperature: keep in original packaging, protect from moisture and light.

Milrinone can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid): - Other phosphodiesterase inhibitors: may cause profound hypotension. - Strong vasodilators (e.g., nitroprusside): increase risk of severe blood pressure drop. - Concurrent inotropes: additive effect on cardiac rhythm leading to arrhythmias.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt desired inotropic response. - Diuretics: can exacerbate electrolyte disturbances. - Anticoagulants: monitor for bleeding if thrombocytopenia occurs. - CYP3A4 inhibitors/inducers: may alter milrinone plasma levels.